The lawsuit says that Medtronic continued to predict that the new insulin pump would be FDA-approved shortly, even as other regulatory issues and recalls in the diabetes division made that less likely.

Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.

After more than three years of treating the Tandem Diabetes Care Control-IQ Technology system as moderate-risk class II, the US FDA has made the designation official. The classification will also apply to future similar devices.

In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.